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Abstract
Background: The study aimed to evaluate the long-term outcome in patients with advanced local recurrent
nasopharyngeal carcinoma (NPC) treated with or without reirradiation.
Methods: A total of 44 patients treated without reirradiation (non-RT + chemotherapy) were matched with 44 patients
treated with reirradiation (re-RT+/-chemtherapy) by age, sex, Karnosky performance score (KPS), rT stage, rN stage, and
time interval between initial radiation and recurrence (TI). Overall survival (OS) rate and time to progression (TTP) rate
were assessed using Kaplan–Meier method, log-rank test, and Cox regression analysis.
Results: From March 2008 to December 2013, a total of 88 well-balanced rT3–4 N0-1 NPC patients were retrospectively
analyzed. After a median follow-up of 27 months (range: 6–85), the 5-year OS rate and TTP rate was 23.4 %, 39.0 % in the
non-RT + chemotherapy group and 27.5 %, 49.8 % in the re-RT+/-chemtherapy group, respectively. Multivariate analysis
showed that significant toxic effect was the only significant prognosticator correlated with OS (HR: 2.15, 95 %
CI = 1.02–4.53, p = 0.044). No statistically significant survival differences were observed between the two treatment
groups in either univariate or multivariate analyses.
Conclusion: Compared with reiradiation, treating advanced local recurrent NPC with chemotherapy alone warrants
further validation in the view of its similar survival and more acceptable toxicities.
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Background
Nasopharyngeal carcinoma (NPC) is the predominant
malignancy arising from the nasopharynx epithelium.
Radiation therapy (RT) is the primary treatment for
NPC due to its radiosensitive behavior and deep-seated
anatomic location. For advanced-stage NPC, concurrent
chemoradiotherapy (CCRT) is the established standard
treatment protocol [1–6]. With the development of modern
radiation and imaging techniques, the local control rate of
NPC has been favorably improved. However, 10–15 % of
patients still experience local recurrence [7–9]. A second
course of RT with the technique of conventional external
beam radiotherapy (EBRT), brachytherapy, and stereotactic
radiosurgery were commonly used as salvage treatment in
the past decades. Nonetheless, both the results of tumor
control and the patient’s quality of life are barely satisfactory
[10–12]. The advent of intensity modulated radiation the-
rapy (IMRT) brought improvement of target coverage and
the sparing of adjacent critical organs [13]. With IMRT,
reirradiation for local recurrent NPC achieved encouraging
tumor control and patient survival; further, the treatment-
related toxicities were acceptable [14–17]. However,
when we went deep into these results, we found that
reirradiation mainly prolongs survival of patients with
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early local recurrent stage disease. The effect of reirra-
diation in the treatment of advanced local recurrent
disease remains uncertain. Moreover, patients with ad-
vanced local failure invariably experienced excessive
risk of severe late complications of reirradiation caused
by extensive tumor infiltration of critical normal tissues
in the vicinity of tumor target that had already received
a high dose of radiation from the primary RT. In view
of these potential RT-related severe toxicities, quite a
few patients with advanced rT stage disease refused to
take the second course of RT. Then chemotherapy
became the alternative treatment method for these
patients. However, chemotherapy has been considered a
palliative therapy in the salvage treatment of local re-
current disease [18, 19]. In fact, the efficacy of chemo-
therapy in treating advanced local recurrent NPC has
not yet been fully evaluated. In our daily clinical work,
survival of these patients was observed to approach the
rate of patients treated with RT. Thus, the aim of this
case-control study is to assess survival of patients with
advanced local recurrent NPC treated with or without
reirradiation. We hypothesize that patients with ad-
vanced local failure treated with chemotherapy alone
(non-RT + chemotherapy) have a survival rate equivalent
to patients treated with RT with or without chemotherapy
(re-RT+/-chemtherapy) but with fewer treatment-related
complications.
Methods
Patients diagnosed with advanced local recurrent NPC
between March 2008 and December 2013 in our insti-
tute were identified. The eligibility criteria included the
following: (1) rT3-4 N0-1 disease according to the 7th edi-
tion of the International Union against Cancer/American
Joint Committee on Cancer (UICC/AJCC) staging system;
(2) with retropharyngeal lymph node metastasis only; (3)
no evidence of distant metastases; (4) aged 18 years or
older; (5) absence of secondary malignancy, pregnancy or
lactation; (6) adequate hematologic function (white blood
cell counts ≥ 4000/μL and platelet counts ≥ 100000/μL),
adequate renal function (creatinine clearance ≥ 50 mL/
min) and adequate hepatic function (serum bilirubin
level < 1.5 mg/dL) before treatment, and (7) treated
with IMRT+/-chemotherapy or chemotherapy alone.
Patients who met the inclusion criteria were divided
into two groups: non-RT + chemotherapy group and re-
RT+/-chemotherapy group. For comparisons, the 44
recurrent patients in the non-RT + chemotherapy group
were individually matched to one control patient in the
re-RT+/-chemotherapy group according to age, sex,
Karnosky performance score (KPS), rT stage, rN stage,
and time interval between initial radiation and recur-
rence (TI). Local recurrence of most patients was proved
by biopsy. Patients with recurrence in inaccessible sites,
such as the cavernous sinus and skull base, were diag-
nosed according to their clinical symptoms and image
manifestations. All of the patients were retrospectively
re-staged according to the seventh edition of the
International Union Against Cancer/American Joint
Committee on Cancer (UICC/AJCC) staging system.
Pretreatment evaluation
All patients were evaluated through a complete physical
examination, fiber-optic nasopharyngoscopy, and complete
blood sampling, including differential cell counts, bio-
chemical profile, and plasma level of EBV DNA measured
by real-time quantitative polymerase chain reaction (PCR)
[20, 21] before treatment. Magnetic resonance imaging
(MRI) of the nasopharynx and neck, chest X-ray, abdom-
inal sonography, electrocardiography, and bone scan, or
18 F-FDG positron emission tomography (PET)/computed
tomography scans were carried out for accurate disease
staging. This retrospective study was approved by the Cli-
nical Research Committee of the study institute.
Chemotherapy
Cisplatin-based chemotherapy (cisplatin alone or cisplatin
plus other one or two anti-tumor drugs, including 5-
fluorouracil, paclitaxel and gemcitabine) was administered
to 37 patients treated with RT and 44 patients without RT.
In the re-RT+/-chemtherapy group, eight patients under-
went concurrent chemotherapy, 17 patients underwent in-
duction chemotherapy, and 12 patients underwent both
induction and concurrent chemotherapy [18, 19, 22, 23].
In the non-RT + chemtherapy group, after undergoing
two to six cycles of chemotherapy, oral tegafur-uracil or
capecitabine was administered to 29 patients for mainten-
ance chemotherapy until disease progression or death.
Radiation therapy
All of the patients in the re-RT+/-chemotherapy group
used IMRT. The IMRT plan was designed according to
the treatment protocol for recurrent NPC at our study
institute. All patients were immobilized in the supine
position with a head, neck, and shoulder thermoplastic
mask. Two sets of images, with and without contrast,
were obtained from the CT simulator for treatment
planning. All patients were scanned with serial 3 mm
slices from the vertex through the clavicles. The imaging
data were transferred to the Corvus inverse planning
system (Peacock, Nomos, Deer Park, IL), and a MiMi
multileaf collimator (Nomos, Sewickly, PA) was used for
planning and treatment.
Tumor volumes were delineated in accordance with
the International Commission on Radiation Units and
Measurements Report 62 (ICRU 62) and ICRU 50. The
delineation of recurrent gross tumor volumes (GTVnx
and GTVnd) was based on the MRI. The clinical tumor
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volume (CTV) included GTV plus a 5 to 10 mm margin
and encompassed the recurrent lymph node. Critical
normal structures, including the brainstem, spinal cord,
parotid glands, optic nerves, chiasm, lens, eyeballs, tem-
poral lobes, temporomandibular joints, mandible, and
hypophysis were contoured and set as organ at risk (OARs)
during optimization. The planning target volume (PTV)
was created based on each volume, with an additional
3 mm margin, allowing for setup variability.
The prescribed dose was 58–70 Gy to the GTV and
50–54 Gy to the CTV in 27 to 35 fractions. The dose–vol-
ume histograms of the treatment targets and critical
normal structures were evaluated. For GTV and CTV, the
target volumes receiving 95 % of the prescribed dose were
used to reflect the target coverage. The dose constraints to
the critical organs were limited by the threshold doses, the
TI after primary RT, and the patient’s performance status.
Outcome and follow-up
The primary endpoint for the study was overall survival
(OS), defined as the time from the day of therapy to the
date of death from any cause or patient censoring at the
date of the final follow-up. The secondary endpoints for
the study were toxic effects and time to progression
(TTP), which was defined as the time to date of treat-
ment failure at any site or patient censoring at the date
of the last follow-up. After the completion of treatment,
patients were examined at least every 3 months during
the first 3 years and had follow-up examinations every
6 months thereafter or until death. Nasopharyngoscopy,
MRI of the head and neck, chest radiography, abdominal
sonography, or PET-CT were routinely performed annu-
ally or upon clinical indication of tumor relapse. Acute
toxicities were classified according to the Common
Toxicity Criteria (CTC) system version 3.0 and were
assessed weekly during retreatment. For patients in the
RT group, the most severe radiation-related toxicities were
assessed and graded based on the Radiation Therapy
Oncology Group (RTOG)/European Organization for
Research and Treatment of Cancer (EORTC) morbidity
scoring system.
Statistical analysis
Statistical analyses were performed using SPSS software
(version 20.0, SPSS Inc., Chicago, IL, USA). Fisher’s exact
test and a χ2 test were used to assess categorical variables,
whereas the t-test and Mann–Whitney U test were used to
analyze continuous variables. The actuarial survival rates
were estimated by the Kaplan–Meier method and survival
curves were compared using the log-rank test. Univariate
and multivariate analyses were performed using the Cox
proportional hazards model. The following factors were
included in the univariate and multivariate analyses:
treatment methods (re-RT+/-chemotherapy or non-RT +
chemtherapy), age, sex, rT stage, rN stage, EBV DNA (=0
copies per milliliter vs. > 0 copies per milliliter), KPS, TI,
and significant toxic effects (Grade3–5 treatment-related
late toxicity). All statistical tests were two-sided, and a P
value of less than 0.05 was considered significant.
Results
The patient characteristics are detailed in Table 1. The
re-RT+/-chemotherapy group and non-RT + chemther-
apy group each had 44 patients. The groups were well
matched for age, sex, KPS, rT stage, rN stage, and TI.











Female 10 (22.7) 10 (22.7)
Male 34 (77.3) 34 (77.3)
Pathology 0.597
WHO type 2–3 36 (81.8) 34 (77.3)
Imaging
manifestation only
8 (18.2) 10 (22.7)
rT stage 1.000
T3 20 (45.6) 20 (45.6)
T4 24 (54.5) 24 (54.5)
rN stage 1.000
N0 33 (75.0) 33 (75.0)
N1 11 (25.0) 11 (25.0)
TI (months) 1.000
> 24 20 (45.6) 20 (45.6)
≤ 24 24 (54.5) 24 (54.5)
Chemotherapy 0.012
Yes 37 (84.1) 44 (100)
No 7 (15.9) 0 (0)
KPS 1.000
> 70 40 (90.9) 40 (90.9)
≤ 70 4 (9.1) 4 (9.1)
Significant toxic effects <0.001
Yes 38 (86.4) 23 (52.3)
No 6 (13.6) 21 (47.7)
Abbreviations: RT radiation therapy, TI time interval between initial radiation
and recurrence, KPS Karnosky performance score, Significant toxic effects Grade
3–5 treatment-related late toxicity, Re-RT+/-chemotherapy radiation therapy
with or without chemotherapy, non-RT + chemotherapy chemotherapy alone
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RT treatment plans
The median minimum, mean, and maximum GTVnx
doses given to the 44 patients were 62.3 Gy (range, 53.9–
73.5 Gy), 66.3 Gy (range, 58.6–77.0 Gy), and 71.2 Gy
(range, 61.5–80.5 Gy), respectively. The median volume of
GTVnx was 54.5 cm3 (range, 15.2–121.8 cm3).
Tumor response assessment
Three months after completion of therapy, the response
of all patients was evaluated by the investigator accord-
ing to the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria [24] as complete response (CR), par-
tial response (PR), stable disease (SD), disease progres-
sion (PD), or not assessable. If the recurrent disease
exhibited a CR or a PR to treatment, we considered the
patient to be a responder. The response rate in the
non-RT + chemtherapy group was 52.3 %: 5 patients
exhibited CR, 18 patients exhibited PR, 17 patients ex-
hibited SD, and 4 patients exhibited PD. The response
rate in the re-RT+/-chemtherapy group was 79.5 %: 12
patients exhibited CR, 23 patients exhibited PR, 8
patients exhibited SD, and 1 patient exhibited PD.
Toxicities
In the re-RT+/-chemtherapy group, different grades of
acute and late toxicities were observed in all patients
(Table 2). The most common acute toxicities included
Grade 1 to 2 mucositis and xerostomia. Eight (18.2 %)
patients suffered from Grade 3 mucositis, 9 (20.5 %)
patients suffered from Grade 3 xerostomia, and 2 (5 %)
patients suffered from Grade 4 mucositis. Grade 3 to 4
anemia, neutropenia, and thrombocytopenia were encoun-
tered in 11 (25.0 %), 16 (36.4 %), and 14 (31.8 %) patients,
respectively. After completion of reirradiation, 17 (38.6 %)
patients experienced nasopharyngeal necrosis, 8 (18.2 %)
patients experienced temporal lobe necrosis, 6 (13.6 %)
patients experienced cranial neuropathy, 21 (47.7 %)
patients experienced hearing loss, and 9 (20.5 %) patients
experienced trismus. Grade 3 to 5 late toxicities were 23
(52.3 %) in the re-RT+/-chemtherapy group during the
follow-up period. In the non-RT + chemtherapy group,
hematological toxicity was the major toxicity observed in
the treatment course. Grade 3 to 4 anemia, neutropenia,
and thrombocytopenia were encountered in 12 (27.3 %),
19 (43.2 %), and 13 (29.5 %) patients. Only one (2.2 %)
patient with neutropenic sepsis was documented. Grade 1
to 2 radiation-related toxicity from the primary RT, in-
cluding xerostomia, hearing loss, trismus, and temporal
lobe necrosis, was observed in the patients in the control
group. Only five (11.4 %) patients developed Grade 3
radiation-related toxicity (2 with xerostomia, 2 with hea-
ring loss, and 1 with temporal lobe necrosis).
Survival
Within the median follow-up duration of 27 months
(range, 6–85 months), 34 developed local failure, 11 ex-
hibited distant metastasis, and 44 patients died. In the
re-RT+/-chemtherapy group, 13 patients died due to
radiation-related injuries (3 from radiation encephalop-
athy, 8 patients from mucosal necrosis or massive
hemorrhage, and 2 patients from other radiation-related
injuries), 4 patients died due to local failures, 3 patients
died due to distant metastasis, 1 patient died due to pneu-
monia, and 1 died due to intracranial infection (Table 3).
In the non-RT + chemtherapy group, 13 patients died due









No 33 (75.0 %) 32 (72.7 %)
Yes 11 (25.0 %) 12 (27.3 %)
Grade3-5 Neutropenia 0.513
No 28 (63.6 %) 25 (56.8 %)
Yes 16 (36.4 %) 19 (43.2 %)
Grade3-5 Thrombocytopenia 0.817
No 30 (68.2 %) 31 (70.5 %)
Yes 14 (31.8 %) 13 (29.5 %)
Grade3-5 Mucositis 0.001
No 34 (77.3 %) 44 (100.0 %)
Yes 10 (22.7 %) 0 (0 %)
Grade3-5 Xerostomia 0.053
No 35 (79.5 %) 42 (95.5 %)
Yes 9 (20.5 %) 2 (4.5 %)
Grade3-5 Nasopharyngeal necrosis <0.001
No 27 (61.4 %) 44 (100.0 %)
Yes 17 (38.6 %) 0 (0 %)
Grade3-5 Temporal lobe necrosis 0.035
No 36 (81.8 %) 43 (97.7 %)
Yes 8 (18.2 %) 1 (2.3 %)
Grade3-5 Cranial neuropathy 0.026
No 38 (86.4 %) 44 (100.0 %)
Yes 6 (13.6 %) 0 (0 %)
Grade3-5 Trismus
No 35 (79.5 %) 44 (100.0 %) 0.002
Yes 9 (20.5 %) 0 (0 %)
Grade3-5 Hearing loss 0.001
No 28 (63.6 %) 42 (95.5 %)
Yes 16 (36.4 %) 2 (4.5 %)
Abbreviations: RT radiation therapy, Re-RT+/-chemotherapy radiation therapy
with or without chemotherapy, non-RT + chemotherapy chemotherapy alone
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to progression of local disease, 3 patients died due to dis-
tant metastasis, 5 patients died due to unknown cause
(Their family members refused to tell the cause of death)
and 1 patient died due to neutropenic sepsis (Table 3).
The 5-year overall survival rate was 23.4 % (95 % CI =
4.6 %–42.2 %) in the non-RT + chemtherapy group and
27.5 % (95 % CI = 8.1 %–46.9 %) in the re-RT+/-chemthe-
rapy group (p = 0.611) (Fig. 1). No statistically significant
survival differences were observed between the two groups.
The 5-year TTP rate was 39.0 % (95 % CI = 22.1 %–55.9 %)
in the non-RT + chemtherapy group and 49.8 % (95 %
CI = 31.8 %–67.8 %) in the re-RT+/-chemtherapy group
(p = 0.087) (Fig. 1). Although the non-RT + chemther-
apy group had about a 10 % higher risk of disease
progression than the re-RT+/-chemtherapy group, the
difference was not significant. Univariate analyses
revealed that KPS (HR: 3.59, 95 % CI = 1.56–8.30, p =
0.003) and significant toxic effects (HR: 1.98, 95 % CI =
1.09–3.59, p = 0.025) were significantly correlated with
OS. Univariate analysis also demonstrated that KPS
(HR: 2.49, 95 % CI = 1.04–5.95, p = 0.041) was signifi-
cantly associated with TTP. Multivariate analyses were
performed to adjust further for various prognostic factors,
including age (>46 years vs. ≤46 years), sex (female vs.
male), rT stage (rT3 vs. rT4), rN stage (rN0 vs. rN1), EBV
DNA (= 0 copies per milliliter vs. > 0 copies per milliliter),
TI (> 24 month vs. ≤ 24 month), KPS (> 70 vs. ≤ 70), sig-
nificant toxic effects (Grade 0–2 treatment-related late
toxicity vs. Grade 3–5 treatment-related late toxicity) and
treatment methods (re-RT+/-chemtherapy vs. non-RT +
chemtherapy). Multivariate analysis revealed that signifi-
cant toxic effects (HR: 2.12, 95 % CI = 1.01–4.47, p =
0.047) was the only significant prognosticator associated
with OS (Table 4). Both univariate and multivariate ana-
lyses demonstrated that patients treated with non-RT +
chemtherapy methods were not associated with higher
risk of death and disease progression than patients treated
with re-RT+/-chemtherapy methods.
Discussion
Management of local recurrent NPC is still a crucial
clinical challenge, especially to patients with advanced
local recurrent disease. Salvage treatment with reirradia-
tion has usually been recommended for improving the
long-term survival. However, a second course of RT al-
ways comes with severe complications. The 5-year sur-
vival rates remain unsatisfactory at about 7 % to 37.0 %
[10–12, 25–27]. As IMRT emerges, with favorable dose
distribution to the tumor target and adjacent critical or-
gans, it has shown a lot of advantages compared with
conventional RT [13, 28]. Kwok et al. reported a large
series on patients with recurrent NPC who received RT.
The 3-year OS rate for patients with isolated local failure
was 74 %. However, in subgroup analysis, salvage treat-
ment was associated with improved OS only in patients
with rT1 to rT2 local failure, but not with rT3 or rT4
disease. Hua et al. reported an impressive 80.7 % local
control rate of 5 years. Although better local control rate
was achieved, the 5-year OS rate was only 38 %, especially
for patients with advanced stage disease. Furthermore, the






Death No. of patients (%) No. of patients (%)
Total 22 22
Local failure 4(18.2) 13(59.1)
Distant metastasis 3(13.6) 3(13.6)
Radiation injuries 13(59.1) 0(0)
Others 2(9.1) 6(27.3)
Abbreviations: NPC nasopharyngeal carcinoma, RT radiation therapy, Re-RT
+/-chemotherapy radiation therapy with or without chemotherapy, non-RT +
chemotherapy chemotherapy alone
Fig. 1 Kaplan–Meier curves of overall survival (a) and time to progression survival (b) in advanced local recurrent NPC patients treated with re-RT
+/-chemtherapy and non-RT + chemotherapy
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incidence of severe late toxicity happened in 39 % patients
with advanced disease [16]. Han et al. analyzed the out-
comes of 239 NPC patients with local failure who were
reirradiated with IMRT. After the follow-up of 29 months
(range: 5–121 months), 120 patients in the study died, and
89 (69.2 %) of them died due to radiation-related injuries
[15]. A recent study conducted by Tian et al. stated that
the heterogeneity of locally recurrent NPC indicates that
not all patients will benefit from reirradiation using IMRT,
because they may experience poor disease control and se-
vere late complications [29]. One of the most important
heterogeneity problems-influenced curative effect is the
recurrent T stage in all these studies. Survival always
yielded to severe toxicity in patients with advanced rT
stage disease. Consequently, quite a few patients with ex-
tensive disease were not willing to take the second course
of RT and most of them chose chemotherapy-based treat-
ment instead in our daily clinical work. However, chemo-
therapy is considered a palliative treatment for advanced
recurrence [18, 19]. The study performed by Wong et al.
is the first systematic study to explore chemotherapy with
or without radiotherapy in patients with recurrent NPC.
In this study, the 2-year progression-free survival rates in
patients treated with RT is better than in patients treated
with chemotherapy alone (58 % vs. 38 %), but the overall
survival of the two groups was similar with about 55 % of
them alive at 2 years. Despite the 58 % remission rate in
the chemoradiotherapy group, patients with extensive
local and/or regional failure in the study still tend to do
poorly with reirradiation [19]. These unsatisfactory results
of chemotherapy could be caused partly by selection bias
of suboptimal performance status and patients with exten-
sive disease. Our study is the first case-control study to
evaluate the outcome of NPC patients with advanced local
failure treated with or without reirradiation. In our study,
patients treated with RT could experience relatively better
long-term remission tendency compared with patients
treated without RT (49.8 % vs. 39.0 %). However, patients
in the non-RT + chemtherapy group achieved a 5-year OS
rate similar to patients treated with re-RT+/-chemtherapy
(23.4 % vs. 27.5 %). In patients with rT3 or rT4 disease,
reirradiation has been reported not to be associated with
improved OS [30]. The lack of survival benefit of reirra-
diation may be due to suboptimal dose distribution in the
large volume of recurrent diseases compromised with crit-
ical organs protection, mortality associated with the
radiation-related complications, radiation resistance of the
recurrent NPC, or fibroplasias after the primary RT of the
nasopharyngeal structures. Treatment toxicity is a crucial
consideration in the decision about salvage treatment for
local recurrent NPC, especially for those with advanced
disease. According to our study, most patients treated
without RT suffered from mild to moderate late toxicity.
Only one patient died due to treatment-related toxicities.
Nevertheless, in the re-RT+/-chemtherapy group, 13 pa-
tients died due to radiation-related injuries, and most of
them suffered from severe radiation-related complications.
The quality of life in these patients is poor. Considering
similar survival benefit and more acceptable toxicities,
treating carefully selected patients with chemotherapy in-
stead of reirradiation would be feasible. The results of the
study might help us choose the optimal treatment method
for advanced local recurrent NPC patients in our daily
clinical work.
However, there are several limitations of our study. First,
the simple size of our study is relatively small, which
might make the results of study underpowered. Second,
this is a retrospective study in a single center. Besides sur-
vival and toxicities, medical cost incurred in an effort to
control or alleviate the symptoms of either complication
or cancer progression in each group is also an important
issues we shoulded concerned. For example, treatment of
cranial neuropathy, surgery or debridement of the naso-
pharyngeal mucusa necrosis and intravenous or oral anti-
tumor drugs to control tumor progression do cost a lot.
Therefore, a prospective study with emphasis on survival,
quality of life measurement and medical cost to control or
Table 4 Multivariate analysis of prognostic factors correlated
with outcome
Endpoint HR (95 % CI) P value
OS
Age 0.91 (0.46–1.81) 0.785
Sex 1.05 (0.45–2.45) 0.920
rT stage 1.12 (0.60–2.35) 0.618
rN stage 0.86 (0.40–1.86) 0.701
EBV DNA 0.67 (0.34–1.32) 0.241
KPS 2.36 (0.90–6.12) 0.082
TI 0.89 (0.46–1.72) 0.730
Significant toxic effects 2.12 (1.01–4.47) 0.047
Treatment method 0.61 (0.31–1.21) 0.158
TTP
Age 0.60 (0.28–1.29) 0.191
Sex 0.90 (0.43–1.91) 0.784
rT stage 1.20 (0.60–2.39) 0.611
rN stage 1.13 (0.53–2.43) 0.750
EBV DNA 1.55 (0.73–3.29) 0.251
KPS 2.10 (0.76–5.81) 0.155
TI 0.89 (0.46–1.73) 0.730
Significant toxic effects 1.21 (0.55–2.67) 0.640
Treatment method 0.49 (0.24–1.02) 0.056
Abbreviations: OS overall survival, TTP time to progression, TI time interval
between initial radiation and recurrence, KPS Karnosky performance score,
Significant toxic effects Grade3–5 treatment-related late toxicity, Treatment
method patients treated with a radiation therapy with or without chemotherapy
or chemotherapy alone
Liu et al. BMC Cancer  (2016) 16:774 Page 6 of 8
alleviate the symptoms of either complication or cancer
progression is warranted to validate the benefit of chemo-
therapy without reirradiation in the treatment of advanced
local recurrent NPC.
Conclusion
In conclusion, our study demonstrated that the patients
with advanced local recurrent NPC receiving chemothrapy
alone without reirradiation achieved equivalent survival
compared with patients treated with RT, and the toxicity is
more acceptable. It would be feasible to treat advanced
local recurrent NPC patients with chemotherapy alone in-
stead of reirradiation. Further investigation is warranted.
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